Myriad Genetics Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 92/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 8.06.In the medium term, the stock price is expected to remain stable.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Myriad Genetics Inc's Score
Industry at a Glance
Industry Ranking
92 / 208
Overall Ranking
221 / 4568
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
13
analysts
Hold
Current Rating
8.064
Target Price
+14.05%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Myriad Genetics Inc Highlights
StrengthsRisks
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 23.47% year-on-year.
Overvalued
The company’s latest PE is -1.51, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 92.00M shares, decreasing 10.78% quarter-over-quarter.
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Ticker SymbolMYGN
CompanyMyriad Genetics Inc
CEORaha (Samraat S)
Websitehttps://myriad.com/
FAQs
What is the current price of Myriad Genetics Inc (MYGN)?
The current price of Myriad Genetics Inc (MYGN) is 6.492.
What is the symbol of Myriad Genetics Inc?
The ticker symbol of Myriad Genetics Inc is MYGN.
What is the 52-week high of Myriad Genetics Inc?
The 52-week high of Myriad Genetics Inc is 15.470.
What is the 52-week low of Myriad Genetics Inc?
The 52-week low of Myriad Genetics Inc is 3.760.
What is the market capitalization of Myriad Genetics Inc?
The market capitalization of Myriad Genetics Inc is 604.42M.
What is the net income of Myriad Genetics Inc?
The net income of Myriad Genetics Inc is -127.30M.
Is Myriad Genetics Inc (MYGN) currently rated as Buy, Hold, or Sell?
According to analysts, Myriad Genetics Inc (MYGN) has an overall rating of Hold, with a price target of 8.064.
What is the Earnings Per Share (EPS TTM) of Myriad Genetics Inc (MYGN)?
The Earnings Per Share (EPS TTM) of Myriad Genetics Inc (MYGN) is -4.347.